Short answer: A US buyer should not compare every non-invasive body-contouring machine as though it delivers the same energy or outcome. The FDA describes light-based heating, radiofrequency (RF) heating and low-level light as different approaches. It also states plainly that non-invasive body contouring does not treat obesity, cause weight loss or supply the health benefits associated with weight loss. A procurement brief should therefore specify the intended body site and cosmetic effect, the exact technology, the authorized indications for the particular model and the risks a provider must explain.
Separate the energy types
The FDA’s body-contouring overview groups technologies into thermal and non-thermal approaches. Its light-based thermal discussion includes powerful light such as lasers or intense pulsed light (IPL), often in the infrared region, used to heat tissue. Its RF section describes electrical energy producing heat; RF is not a laser or IPL simply because all can be offered in an aesthetic clinic. The FDA’s low-level light section describes a non-thermal approach that may use lamps or LED panels. A broad advertisement for a “light body-sculpting device” could conceal material differences in mechanism, operating controls, protective equipment and evidence. Ask which of these mechanisms the offered device actually uses.
Indications are equally important. The FDA describes possible changes in a local bulge, circumference or cellulite appearance, often temporary. Those are not synonyms for sustained weight reduction or metabolic improvement. A buyer should request the specific FDA marketing authorization and labeled use, if claimed, rather than accept a supplier’s generic reference to an FDA page. The page explains technology categories; it is not evidence that any particular TUOKE device has been cleared or approved.
Build an operator-facing comparison
Ask each vendor for a model number, instructions, intended users, treatment sites, expected treatment course, contraindications, eye protection and service requirements. Compare the offered indication with the proposed advertising copy and client consent form. A clinic should ask who decides whether a client is appropriate for treatment and what happens when an outcome is not achieved. The FDA notes that results may be temporary or may not meet expectations, and that some clients need more than one procedure. An honest commercial forecast should allow for consultation time, maintenance and follow-up rather than assuming a single-session result for everyone.
The risk sheet should be technology-specific. The FDA identifies eye-injury potential for light-based procedures and discusses light sensitivity, tanning and some skin responses. RF carries a different set of cautions, including implanted devices or metal in certain circumstances. The FDA’s examples of complications include discomfort, redness, swelling and possible burns or color change depending on the method. These are prompts for qualified clinical and safety review, not instructions for selecting settings or treating a client.
Limits of this guidance
This FDA page is standing US consumer and device information, not a new 2026 market launch. It covers more than optical equipment and does not establish that every body-contouring service is regulated identically. Legal status and safe use depend on the exact device, intended use and location. The article provides a purchasing framework, not clinical advice or a claim of therapeutic benefit. Read the manufacturer’s current labeling and obtain appropriate professional advice before offering a procedure or publishing a medical claim.
For broader context on evaluating technology claims, see TUOKE’s optical aesthetic equipment insights. No category page should substitute for model-specific evidence.
Source
US Food and Drug Administration, Non-Invasive Body Contouring Technologies, undated standing guidance; reviewed 15 October 2026.